Clinical Trial Search

Primary: Summary for Change From Baseline of Mean Global Semi-quantitative Score Values for Neutrophils in Bronchial Biopsies — -1.21 Units on a scale

Primary: AUC — 113.5; 114.6; 423.7; 1042 h*ng/mL

Primary: Maximum Observed Plasma Concentration (Cmax) — 10.7; 9.00; 8.03; 3.97 nanograms per milliliter (ng/mL)

Primary: Number of Participants With Clinically Significant Hypocalcemia — 1; 2 participants

Primary: Number of Subjects (3 to <9 Years of Age) Reporting Solicited Adverse Events (AEs) Following Vaccination With H3N2 Monovalent Vaccine. — 31; 36; 18; 24 Number of Subjects

Primary: Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUC Last) (Dose Normalized to 1 mg) and Absolute Oral…

Primary: Change From Baseline to End of Study in Number of Rectal Polyps — -5.4; -1.6; -3.5 polyps — p=0.065

Primary: Change in Dynamic Gait Index (DGI) From Baseline to 6 Weeks. — 4.3 units on a scale

Primary: Number of Subjects With Drug Related Adverse Events (AE) — 2; 0; 0; 0 participants

Primary: Maximum Plasma Concentration (Cmax) of Oseltamivir in HD Participants During Days 1 to 5 — 20.2 ng/mL

Primary: MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib). — NA; 40 mg

Primary: Geometric Mean Concentrations (GMCs) of Antibodies in aP1, aP2, aP4 Groups Against Pertussis Antigens at Day 1. — 28; 31; 48; 18 IU/mL

Primary: Reversal of Dabigatran-induced Prolongation of Blood Coagulation Time — 0.0; 100.0; 0.0; 100.0 percentage of participants

Primary: Percentage of Subjects With Drug-related Adverse Events in Part 1 and Part 2 — 16.7; 0.0; 0.0; 0.0 Percentage of participants

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants